Insider trading · Q3 2026 · CIK 1625297

Indivior Pharmaceuticals, Inc. (INDV) insider trading.

In Q3 2026, insiders at Indivior Pharmaceuticals, Inc. reported 3 non-derivative transactions on 3 Forms 3, 4 and 5: 2 open-market purchases worth $108K and 1 sale worth $765K.

Transactions
3
Purchases (P)
2
Sales (S)
1
Net shares, P minus S
-15,586
Insiders
2
Last filed
2026-08-27

Insiders

InsiderRelationshipTransactionsBuysSales
Anderson Woodrow DOfficer · Chief Accounting Officer220
Heidbreder ChristianOfficer · Chief Scientific Officer101

Transactions

3 non-derivative rows, newest transaction first. Shares and prices as filed.
DateInsiderCodeSharesPriceOwned afterFiling
2026-08-27Anderson Woodrow DP (A)1,500$35.6927,638Form 4
2026-08-05Anderson Woodrow DP (A)1,500$36.2826,138Form 4
2026-07-10Heidbreder ChristianS (D)18,586$41.14209,337Form 4

Transaction codes in this quarter

Get INDV insider transactions through the API

Request with your API key
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1625297&limit=100" \
  -H "Authorization: Bearer $SEC_API_KEY"

Insider trading API guide · INDV company page · Indivior Pharmaceuticals, Inc. on SEC.gov

Questions

Are insiders buying or selling Indivior Pharmaceuticals, Inc. (INDV)?

In Q3 2026, insiders at Indivior Pharmaceuticals, Inc. reported 3 non-derivative transactions on 3 Forms 3, 4 and 5: 2 open-market purchases worth $108K and 1 sale worth $765K. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.

Where do these Indivior Pharmaceuticals, Inc. insider trades come from?

From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.

Source: SEC Insider Transactions Data Sets, Q3 2026, retrieved 2026-10-27. Footnotes, derivative holdings and amendments are in the linked filings. Not investment advice.

Plain-text version for agents and LLMs: /insider-trading/indv.md

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.